Letermovir (Prevymis) for CMV Prophylaxis

Date: December 16, 2019 Issue #:  1587Summary:  The FDA has approved letermovir (Prevymis– Merck), a cytomegalovirus (CMV) DNA terminase complex inhibitor, for prophylaxis of CMV infection and disease in CMV-seropositive adult recipients of an allogeneic hematopoietic cell transplant (HCT). Letermovir is the first CMV DNA terminase complex inhibitor to be approved in the US and the on ly drug specifically indicated for CMV prophylaxis in HCT patients. It is not approved for treatment of CMV infection.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Cidofovir Cytovene Foscarnet Foscavir Ganciclovir letermovir Prevymis Valcyte Valganciclovir Source Type: research